# Nuwellis, Inc.: overview NUWE · Nasdaq · CIK 1506492 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/nuwe.md) · [Financials](/companies/nuwe/financials.md) · [Filings](/companies/nuwe/filings.md) · [Insiders](/companies/nuwe/insiders.md) Latest reported revenue: [$2.0m](/filings/0001140361-26-032810.md) for Q2 FY2027, three months to 2026-06-30, from the 10-Q filed Aug 13, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001140361-26-032810). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2027 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [2,367](/filings/0001140361-25-041651.md) | [2,322 d](/filings/0001140361-26-009080.md) | [1,904](/filings/0001140361-26-021649.md) | [1,725](/filings/0001140361-26-032810.md) | [2,217](/filings/0001140361-25-041651.md) | [2,424 d](/filings/0001140361-26-009080.md) | [2,403](/filings/0001140361-26-021649.md) | [1,969](/filings/0001140361-26-032810.md) | | Gross margin | % | [70.0%](/filings/0001140361-25-041651.md) | [58.4% d](/filings/0001140361-26-009080.md) | [56.0%](/filings/0001140361-26-021649.md) | [55.5%](/filings/0001140361-26-032810.md) | [65.2%](/filings/0001140361-25-041651.md) | [68.2% d](/filings/0001140361-26-009080.md) | [70.1%](/filings/0001140361-26-021649.md) | [76.1%](/filings/0001140361-26-032810.md) | | Operating margin | % | [(64.7%)](/filings/0001140361-25-041651.md) | [(102.8%) d](/filings/0001140361-26-009080.md) | [(160.7%)](/filings/0001140361-26-021649.md) | [(168.5%)](/filings/0001140361-26-032810.md) | [(121.7%)](/filings/0001140361-25-041651.md) | [(100.8%) d](/filings/0001140361-26-009080.md) | [(190.1%)](/filings/0001140361-26-021649.md) | [(160.9%)](/filings/0001140361-26-032810.md) | | Net margin | % | [99.6%](/filings/0001140361-25-041651.md) | [(63.2%) d](/filings/0001140361-26-009080.md) | [(158.3%)](/filings/0001140361-26-032810.md) | [(727.7%)](/filings/0001140361-26-032810.md) | [21.1%](/filings/0001140361-25-041651.md) | [(99.9%) d](/filings/0001140361-26-009080.md) | [(189.0%)](/filings/0001140361-26-032810.md) | [(245.2%)](/filings/0001140361-26-032810.md) | | Diluted EPS | $ per share | [73.23](/filings/0001140361-25-041651.md) | not reported | [(28.93)](/filings/0001140361-26-021649.md) | [(2134.19)](/filings/0001140361-26-032810.md) | [0.56](/filings/0001140361-25-041651.md) | not reported | [(2.19)](/filings/0001140361-26-021649.md) | [(26.64)](/filings/0001140361-26-032810.md) | | Free cash flow | $k | [(2,487) d](/filings/0001140361-25-041651.md) | [(1,527) d](/filings/0001140361-26-009080.md) | [(2,536)](/filings/0001140361-26-021649.md) | [(2,101) d](/filings/0001140361-26-032810.md) | [(3,245) d](/filings/0001140361-25-041651.md) | [(3,042) d](/filings/0001140361-26-009080.md) | [(3,142)](/filings/0001140361-26-021649.md) | [(3,184) d](/filings/0001140361-26-032810.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [7.9](/filings/0001140361-23-010112.md) | [8.5](/filings/0001140361-24-012644.md) | [8.9](/filings/0001140361-25-008124.md) | [8.7](/filings/0001140361-26-009080.md) | [8.3](/filings/0001140361-26-009080.md) | | Gross margin | % | [56.7%](/filings/0001140361-23-010112.md) | [55.7%](/filings/0001140361-24-012644.md) | [56.2%](/filings/0001140361-25-008124.md) | [64.9%](/filings/0001140361-26-009080.md) | [62.0%](/filings/0001140361-26-009080.md) | | Operating margin | % | [(246.5%)](/filings/0001140361-23-010112.md) | [(201.0%)](/filings/0001140361-24-012644.md) | [(198.9%)](/filings/0001140361-25-008124.md) | [(125.7%)](/filings/0001140361-26-009080.md) | [(134.3%)](/filings/0001140361-26-009080.md) | | Net margin | % | [(246.9%)](/filings/0001140361-23-010112.md) | [(170.0%)](/filings/0001140361-24-012644.md) | [(228.0%)](/filings/0001140361-25-008124.md) | [(127.7%)](/filings/0001140361-26-009080.md) | [(211.9%)](/filings/0001140361-26-009080.md) | | Diluted EPS | $ per share | [(285.36)](/filings/0001140361-23-010112.md) | [(83.55)](/filings/0001140361-24-012644.md) | [(360.06)](/filings/0001140361-25-008124.md) | [(353.30)](/filings/0001140361-26-009080.md) | [(25.39)](/filings/0001140361-26-009080.md) | | Free cash flow | $m | [(18.1)](/filings/0001140361-23-010112.md) | [(15.3)](/filings/0001140361-24-012644.md) | [(18.1)](/filings/0001140361-25-008124.md) | [(9.7)](/filings/0001140361-26-009080.md) | [(10.9)](/filings/0001140361-26-009080.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/nuwe/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [SABBY MANAGEMENT, LLC](/funds/1535610.md) | 2026-06-30 | $49.9k | 16,372 | | New +16,372 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $13.5k | 4,415 | | New +4,415 | | [Tower Research Capital LLC (TRC)](/funds/1533421.md) | 2026-06-30 | $421 | 138 | | New +138 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $107 | 35 | | New +35 | | [SBI Securities Co., Ltd.](/funds/1851815.md) | 2026-06-30 | $12 | 4 | | New +4 | ## Recent filings [All 1,086 filings](/companies/nuwe/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-23 | 09:18 ET | [8-K](/filings/0001140361-26-040605.md) | 3.03 Change to security holders’ rights; 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001140361-26-040605 | | 2026-08-26 | 21:26 ET | [8-K](/filings/0001140361-26-034367.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-26-034367 | | 2026-08-13 | 16:38 ET | [8-K](/filings/0001140361-26-032838.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001140361-26-032838 | | 2026-08-13 | 16:06 ET | [10-Q](/filings/0001140361-26-032810.md) | Quarterly report, period 2026-06-30 | 0001140361-26-032810 | | 2026-08-03 | 16:35 ET | [8-K](/filings/0001140361-26-030985.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-26-030985 | | 2026-07-24 | 16:15 ET | [8-K](/filings/0001140361-26-029609.md) | 5.07 Shareholder vote results | 0001140361-26-029609 | | 2026-07-07 | 16:30 ET | [DEF 14A](/filings/0001539497-26-001914.md) | Proxy statement, period 2026-07-07 | 0001539497-26-001914 | | 2026-06-24 | 17:47 ET | [8-K](/filings/0001140361-26-026114.md) | 3.03 Change to security holders’ rights; 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001140361-26-026114 | | 2026-06-18 | 17:59 ET | [8-K](/filings/0001140361-26-025614.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-26-025614 | | 2026-06-10 | 09:09 ET | [8-K](/filings/0001140361-26-024740.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-26-024740 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001140361-26-009080.md), filed Mar 11, 2026. ## Forecast league Q3 FY2027, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/49bbca40-2437-4759-8d9a-94ba5443d492) ## About the filer - CIK: 1506492 - Tickers: NUWE - Exchange: Nasdaq - SIC code: 3845 Electromedical & Electrotherapeutic Apparatus - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:41 ET. No prices; not investment advice.